Phase 1/2a study of double immune suppression blockade by combining a

Discussion Board › Forums › Clinical Trials › Phase 1/2a study of double immune suppression blockade by combining a

Viewing 1 post (of 1 total)
  • Author
    Posts
  • January 26, 2016 at 6:38 pm #12125
    gavin
    Moderator

    Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors.

    http://abstracts.asco.org/173/AbstView_173_159443.html

  • Author
    Posts
Viewing 1 post (of 1 total)
  • The forum ‘Clinical Trials’ is closed to new topics and replies.